HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein.

Abstract
Cell-surface molecules containing growth factor receptors, adhesion molecules and transporter proteins are often over-expressed in various cancer cells, and could be regarded as suitable targets for therapeutic monoclonal antibodies (mAb). Anti-cancer therapeutic mAb are claimed to bind these cell-surface molecules on viable cancer cells: therefore, it is necessary to produce mAb recognizing epitopes on the extracellular domains of native but not denatured proteins. We have experienced difficulty in obtaining mAb bound to viable cancer cells using synthetic peptides or recombinant proteins produced in bacteria as immunogens, although these immunogens are relatively easy to prepare. In this context, we have concluded that viable cancer cells or cells transfected with cDNA encoding target proteins are suitable immunogens for the production of anti-cancer therapeutic mAb. Furthermore, we selected rats as the immunized animals, because of their excellent capacity to generate diverse antibodies. Because many target candidates are multi-pass (type IV) membrane proteins, such as 7-pass G protein-coupled receptors and 12-pass transporter proteins belonging to the solute carrier family, and their possible immunogenic extracellular regions are very small, production of specific mAb was extremely difficult. In this review, we summarize the successful preparation and characterization of rat mAb immunized against the extracellular domain of type I, type II and type IV membrane oncoproteins fused to green fluorescent protein as an approach using reverse genetics, and also introduce the discovery of cell-death-inducing antibodies as an approach using forward genetics and a strategy to produce reshaped antibodies using mimotope peptides as the immunogen.
AuthorsTakashi Masuko, Yoshiya Ohno, Kazue Masuko, Hideki Yagi, Shinya Uejima, Masayuki Takechi, Yoshiyuki Hashimoto
JournalCancer science (Cancer Sci) Vol. 102 Issue 1 Pg. 25-35 (Jan 2011) ISSN: 1349-7006 [Electronic] England
PMID21040216 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2010 Japanese Cancer Association.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Hyaluronan Receptors
  • Membrane Proteins
  • Oncogene Proteins
  • Peptide Library
  • Receptors, Transferrin
  • Recombinant Fusion Proteins
  • Green Fluorescent Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (biosynthesis, therapeutic use)
  • Antibodies, Neoplasm (therapeutic use)
  • Cell Line
  • Green Fluorescent Proteins (genetics)
  • Humans
  • Hyaluronan Receptors (immunology)
  • Immunization
  • Membrane Proteins (immunology)
  • Oncogene Proteins (genetics, immunology)
  • Peptide Library
  • Rats
  • Receptors, Transferrin (immunology)
  • Recombinant Fusion Proteins (biosynthesis)
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: